Reliance Life gets SEC nod for clinical trials of 2-dose Covid-19 vaccine1 min read . Updated: 27 Aug 2021, 02:45 PM IST
- The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance's recombinant Covid vaccine candidate
Mukesh Ambani-owned Reliance Life Sciences, part of the country's largest conglomerate, is expected to start phase I clinical studies of its indigenous coronavirus vaccine soon.
The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance's recombinant Covid vaccine candidate.
Earlier, Reliance Life Sciences had sought approval for the Phase I trial of its proposed two-dose coronavirus vaccine.
The Covid vaccine is being developed at the firm's Navi Mumbai facility, and is expected to be "competitively priced". The company has received approval during the meeting of the SEC on Friday.
After recommendations from SEC, the company is required to get approval from the Drug Controller General of India (DCGI), following which the Reliance Life Sciences can commence Phase 1 trials of the COVID-19 vaccine.
The trials will be done at 10 sites in India that includes centres in Tamil Nadu, Andhra Pradesh, Maharashtra and Delhi.
Phase 1 of the trial usually lasts for 58 days to detect the highest dose that most patients can tolerate.
In India, six Covid-19 vaccines have received Emergency Use Authorization (EUA) till now, which includes Serum Institute of India's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's vaccine, Russia's Sputnik V, Moderna and Johnson and Johnson.
Never miss a story! Stay connected and informed with Mint. Download our App Now!!